McKesson ( (MCK) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
McKesson shares are under pressure as investors worry that changing prices for GLP-1 drugs could squeeze profit margins for drug distributors ahead of the company’s fourth-quarter fiscal 2026 results on May 7. The move reflects broader concerns across the pharmaceutical distribution sector, adding to pre-earnings jitters.
The sell-off has been compounded by fresh price target cuts from Bank of America and UBS, which signal growing skepticism about the company’s near-term earnings power. These analyst moves are reinforcing the negative sentiment around McKesson and its peers as the market reassesses margin expectations.
More about McKesson
YTD Price Performance: -1.43%
Average Trading Volume: 783,685
Technical Sentiment Signal: Buy
Current Market Cap: $98.95B
For further insights into MCK stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.